Austin Hospital-Olivia Newton John Cancer Research Institute
Welcome,         Profile    Billing    Logout  
 8 Trials 
9 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Gan, Hui
GBM AGILE, NCT03970447 / 2020-002250-24: A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

Calendar Jan 2030 - Dec 2030: Market entry for glioblastoma
Oct 2023 - Dec 2023: Top-line data from GBM AGILE trial for glioblastoma
Recruiting
2/3
1030
Europe, Canada, US, RoW
Temozolomide, Temodar, Temodal, Temcad, Lomustine, CCNU, CeeNU, Gleostine, Regorafenib, Stivarga, BAY 73-4506, Radiation, Paxalisib, GDC-0084, VAL-083, Dianhydrogalactitol, VT1021, Troriluzole, BHV-4157, ADI-PEG 20, Pegargiminase
Global Coalition for Adaptive Research, Bayer, Kazia Therapeutics Limited, Kintara Therapeutics, Inc., Biohaven Pharmaceuticals, Inc., Vigeo Therapeutics, Inc., Polaris Group
Glioblastoma
06/26
06/28
TCaP, NCT06157541: T Cells and Pembrolizumab for Recurrent and Newly Diagnosed Glioblastoma

Recruiting
1/2
58
RoW
Allogeneic cytomegalovirus-specific T cells, CYT-101, Pembrolizumab, Keytruda
Queensland Institute of Medical Research, CUREator, Merck Sharp & Dohme LLC, The Newro Foundation, Royal Brisbane and Women's Hospital, Princess Alexandra Hospital, Brisbane, Australia, Austin Hospital, Melbourne Australia
Glioblastoma Multiforme, Astrocytoma, Grade IV
04/26
01/28
ERASER, NCT04305249: Safety and Preliminary Efficacy of ATG-017 Monotherapy or Combination Therapy With Nivolumab in Advanced Solid Tumors and Hematological Malignancies

Terminated
1
36
RoW
ATG-017, AZD0364 hemi-adipic acid, ATG-017+Nivolumab, AZD0364 hemi-adipic acid+Opdivo
Antengene Therapeutics Limited, Bristol-Myers Squibb
Solid Tumor, Hematological Malignancy
04/24
05/24
ATRIUM, NCT05338346: A Study of ATG-018 (ATR Inhibitor) Treatment in Patients With Advanced Solid Tumors and Hematological Malignancies

Terminated
1
22
RoW
ATG-018
Antengene Discovery Limited
Advanced Solid Tumors, Hematological Malignancies
01/24
01/24
KEYNOTE-F49, NCT05763004: A Clinical Study to Evaluate the Safety, Tolerability and Efficacy of IOS-1002 Administered Alone and in Combination with Pembrolizumab, a PD-1 Monoclonal Antibody in Advanced Solid Tumors

Recruiting
1
140
RoW
IOS-1002, IOS-1002 + KEYTRUDA® (pembrolizumab)
ImmunOs Therapeutics AG, Merck Sharp & Dohme LLC
Solid Tumor, Adult
05/25
05/25
NCT06341647: Phase 1 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-201

Not yet recruiting
1
48
RoW
AB-201, Cyclophosphamide, Fludarabine
GC Cell Corporation
Breast Cancer, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
04/27
02/29
NCT06929663: A Study of AK146D1 for Injection in the Treatment of Advanced Solid Tumors

Not yet recruiting
1
48
NA
AK146D1 for injection
Akeso
Advanced Solid Tumors
11/26
05/27
PROBE, NCT04986865: A Study ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas

Recruiting
1
40
US, RoW
ATG-101
Antengene Biologics Limited
Advanced Solid Tumor, Metastatic Solid Tumor, Mature B-cell Non-Hodgkin Lymphoma
10/25
01/26
NCT04127981: Medical Imaging of Cachexia

Recruiting
N/A
40
RoW
18F-FDG PET + Dexa Scan
Olivia Newton-John Cancer Research Institute, La Trobe University, Austin Health
Cancer Cachexia
12/23
12/23
Hakanson, Joanne
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Gan, Hui
GBM AGILE, NCT03970447 / 2020-002250-24: A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

Calendar Jan 2030 - Dec 2030: Market entry for glioblastoma
Oct 2023 - Dec 2023: Top-line data from GBM AGILE trial for glioblastoma
Recruiting
2/3
1030
Europe, Canada, US, RoW
Temozolomide, Temodar, Temodal, Temcad, Lomustine, CCNU, CeeNU, Gleostine, Regorafenib, Stivarga, BAY 73-4506, Radiation, Paxalisib, GDC-0084, VAL-083, Dianhydrogalactitol, VT1021, Troriluzole, BHV-4157, ADI-PEG 20, Pegargiminase
Global Coalition for Adaptive Research, Bayer, Kazia Therapeutics Limited, Kintara Therapeutics, Inc., Biohaven Pharmaceuticals, Inc., Vigeo Therapeutics, Inc., Polaris Group
Glioblastoma
06/26
06/28
TCaP, NCT06157541: T Cells and Pembrolizumab for Recurrent and Newly Diagnosed Glioblastoma

Recruiting
1/2
58
RoW
Allogeneic cytomegalovirus-specific T cells, CYT-101, Pembrolizumab, Keytruda
Queensland Institute of Medical Research, CUREator, Merck Sharp & Dohme LLC, The Newro Foundation, Royal Brisbane and Women's Hospital, Princess Alexandra Hospital, Brisbane, Australia, Austin Hospital, Melbourne Australia
Glioblastoma Multiforme, Astrocytoma, Grade IV
04/26
01/28
ERASER, NCT04305249: Safety and Preliminary Efficacy of ATG-017 Monotherapy or Combination Therapy With Nivolumab in Advanced Solid Tumors and Hematological Malignancies

Terminated
1
36
RoW
ATG-017, AZD0364 hemi-adipic acid, ATG-017+Nivolumab, AZD0364 hemi-adipic acid+Opdivo
Antengene Therapeutics Limited, Bristol-Myers Squibb
Solid Tumor, Hematological Malignancy
04/24
05/24
ATRIUM, NCT05338346: A Study of ATG-018 (ATR Inhibitor) Treatment in Patients With Advanced Solid Tumors and Hematological Malignancies

Terminated
1
22
RoW
ATG-018
Antengene Discovery Limited
Advanced Solid Tumors, Hematological Malignancies
01/24
01/24
KEYNOTE-F49, NCT05763004: A Clinical Study to Evaluate the Safety, Tolerability and Efficacy of IOS-1002 Administered Alone and in Combination with Pembrolizumab, a PD-1 Monoclonal Antibody in Advanced Solid Tumors

Recruiting
1
140
RoW
IOS-1002, IOS-1002 + KEYTRUDA® (pembrolizumab)
ImmunOs Therapeutics AG, Merck Sharp & Dohme LLC
Solid Tumor, Adult
05/25
05/25
NCT06341647: Phase 1 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-201

Not yet recruiting
1
48
RoW
AB-201, Cyclophosphamide, Fludarabine
GC Cell Corporation
Breast Cancer, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
04/27
02/29
NCT06929663: A Study of AK146D1 for Injection in the Treatment of Advanced Solid Tumors

Not yet recruiting
1
48
NA
AK146D1 for injection
Akeso
Advanced Solid Tumors
11/26
05/27
PROBE, NCT04986865: A Study ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas

Recruiting
1
40
US, RoW
ATG-101
Antengene Biologics Limited
Advanced Solid Tumor, Metastatic Solid Tumor, Mature B-cell Non-Hodgkin Lymphoma
10/25
01/26
NCT04127981: Medical Imaging of Cachexia

Recruiting
N/A
40
RoW
18F-FDG PET + Dexa Scan
Olivia Newton-John Cancer Research Institute, La Trobe University, Austin Health
Cancer Cachexia
12/23
12/23
Hakanson, Joanne
No trials found

Download Options